Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian...
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily...
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients...
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individuals Preclinical data for BGM1812 supports...
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions...
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
HONG KONG, June 16, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the...
![G-DRAGON 2025 WORLD TOUR [Übermensch] IN MACAU, QQ MUSIC Attracts Over 7 Million Simultaneous Users](http://prnewswire.vietreader.com/thumb/190x300/2025-06/g-dragon-2025-world-tour-ubermensch-in-macau-qq-music-attracts-over-7-million-simultaneous-users-1.jpg)
G-DRAGON 2025 WORLD TOUR [Übermensch] IN MACAU, QQ MUSIC Attracts Over 7 Million Simultaneous Users
SHENZHEN, China, June 10, 2025 /PRNewswire/ -- Promoted by AEG Presents, TME live and Chessman, G-DRAGON 2025 WORLD TOUR [Übermensch] IN MACAU, presented by Galaxy Macau™, is sponsored by The Hong Kong and Shanghai Banking Corporation Limited...
Top Michelin Chefs Steer a 10-Star Epicurean Adventure Through East Asia at the Third Edition of MGM x RR1HK Culinary Masters Macau
Exemplifying Gastronomic Excellence in a Harmonious Blend to Celebrate Macau as the Creative City of Gastronomy and the Culture City of East Asia MACAU, June 10, 2025 /PRNewswire/ -- MGM x RR1HK Culinary Masters Macau 2025, the highly anticipated...
Wingderm® Strengthens Presence in Asia at IMCAS Asia 2025
BEIJING, June 10, 2025 /PRNewswire/ -- From June 6 to 8, 2025, IMCAS Asia was successfully held in Bangkok, Thailand. As one of the world's leading medical aesthetic events, IMCAS Asia brought together the latest developments and trends in the Asian...
Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach
Phase IIa study results of Rentosertib were published simultaneously in Nature Medicine(IF = 58.7) and presented at the American Thoracic Society (ATS) 2025. Encouraging clinical data showed that patients receiving 60 mg QD Rentosertib experienced...